Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

Model scores of the 29,894 trials active now.

Model score 28% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellradiationtumorchemotherapytherapy
  Phrases that lowered it: prostategrouppsatrialclinical
• Sponsor's past termination rate: 23.8% (raises risk) · Sponsor's track record
• Phase: 1/2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Maximum age: 85 (lowers risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past trials: 21 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 22.1% (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 93.2% (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy NCT00528866 · started 2008 · scored riskier than 68% of active trials completed
• Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer NCT00651326 · started 2008 · scored riskier than 88% of active trials terminated
• Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer NCT00936390 · started 2009 · scored riskier than 60% of active trials completed
• Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer NCT02494713 · started 2015 · scored riskier than 95% of active trials terminated
• External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer NCT01603420 · started 2012 · scored riskier than 93% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.